AOD-9604: Does It Work, Safety, and Legal Status

AOD-9604 is a synthetic peptide made of residues 177-191 of human growth hormone with an added tyrosine at one end. In obese rodents it increased fat breakdown without affecting glucose, insulin or insulin sensitivity. A beta-adrenergic pathway has been proposed from animal work.

That mechanism remains a preclinical hypothesis. A pathway observed in a selected animal model does not demonstrate a meaningful effect in humans, and the proposed beta-3 adrenergic pathway has not been confirmed in human fat tissue.

Multiple controlled human studies were conducted, including larger studies in adults with obesity. The development program did not establish a statistically meaningful weight-loss effect versus placebo and was discontinued for lack of efficacy.

An FDA advisory committee briefing from 2024 summarizes the program and says that in most studies FDA identified, AOD-9604 failed to show benefit for weight reduction compared with placebo. An earlier 12-week trial in about 300 adults is described only in a meeting abstract; its authors reported more weight loss than placebo, and FDA judged the differences small and the data too limited to interpret. A larger 24-week trial in 536 adults then missed its primary weight-loss endpoint, and the developer ended work on AOD-9604 for obesity in February 2007.

A published pooled safety review described tolerability and biochemical findings from the program. It is important to separate that question from efficacy and to note the authors’ disclosed industry ties.

The pooled safety summary covered six randomized, placebo-controlled trials in about 900 adults. It reported no effect on IGF-1 levels or glucose tolerance, no antibodies against AOD-9604 in the participants tested, and no treatment-related withdrawals or serious adverse events. The developer, Metabolic Pharmaceuticals, funded all six trials, and the authors declared financial ties to it.

FDA's review for compounding was more cautious. It found no, or only limited, safety information, noted a possible risk of immune reactions and impurities, and identified serious adverse events that may be associated with AOD-9604, though causality was not clear. A 2026 review of peptides used for injuries and athletic performance also describes rigorous human safety data as scarce.

Claims involving cartilage, joints, or broad metabolic benefit are not supported by adequate controlled human outcome trials. A mechanistic rationale or an uncontrolled signal is not a substitute for a relevant clinical comparison.

The cartilage claim traces mainly to a rabbit osteoarthritis experiment in which AOD-9604 was placed directly into the joint. That is species-specific preclinical evidence, not human efficacy.

AOD-9604 is not approved by the U.S. Food and Drug Administration or Health Canada as a treatment. FDA lists it among bulk drug substances nominated for compounding but withdrawn by the nominator after being placed in category 2 for potential significant safety risks. It is listed by the World Anti-Doping Agency among prohibited peptide hormones, growth factors, related substances, and mimetics. Competitive athletes should rely on current anti-doping rules and qualified sport-medicine guidance.